Comparing Entyvio vs Yesintek
| Entyvio (vedolizumab) | Yesintek (ustekinumab) |
|
|---|
| Entyvio (vedolizumab) | Yesintek (ustekinumab) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Entyvio infusion is an integrin receptor antagonist that may be used to reduce inflammation associated with moderate to severe ulcerative colitis or Crohn's disease. It targets the gut specifically... View more |
Prescription only
Prescribed for Crohn's Disease, Crohn's Disease - Active, Plaque Psoriasis, Psoriasis, Psoriatic Arthritis, Ulcerative Colitis, Ulcerative Colitis - Active. Yesintek may also be used for purposes not... View more |
Related suggestions Ulcerative Colitis
Crohn's Disease
|
|||||||||||||||
| More about Entyvio (vedolizumab) | More about Yesintek (ustekinumab) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Entyvio has an average rating of 6.3 out of 10 from a total of 168 ratings on Drugs.com. 49% of reviewers reported a positive effect, while 27% reported a negative effect. |
Be the first to share your experience with this drug. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
View all Entyvio side effects |
View all Yesintek side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Entyvio prices |
View all Yesintek prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
| Other vedolizumab brands include: Entyvio Pen | Other ustekinumab brands include: Imuldosa, Otulfi, Pyzchiva, Selarsdi, Starjemza, Stelara, Steqeyma, Wezlana | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
600 hours |
1291.2 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 171 drugs are known to interact with Entyvio:
|
A total of 543 drugs are known to interact with Yesintek:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
May 20, 2014 |
November 29, 2024 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.